KCT0007050终止未知
Single Center, Randomized, Open label, Prospective Clinical Trial of BioFire FilmArray assay for antimicrobial treatment of hospital-acquired or ventilator-associated pneumonia in intensive care units
试验速览
- 阶段
- 未知
- 状态
- 终止
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •Inclusion criteria
- •1) Aged 19 years or older
- •2) Diagnosed with hospital-acquired or ventilator-associated pneumonia and being treated in an intensive care unit
- •3) Patient or his/her legal proxy agrees to participate and is able to provide informed consent
排除标准
- •Exclusion criteria
- •1) Has been treated with antibiotic for HAP/VAP for 24 hr or longer
- •2) Requires antibiotic treatment for indications other than HAP/VAP
- •3) Bacteria has been isolated from respiratory specimens within 7 days prior to screening
- •4) Immunocompromised host whose major differential diagnosis includes Pneumocystis jirovecii or cytomegalovirus pneumonia
- •5) Expected to die within 2 days since screening due to underlying disease
- •6) Has an advance directive against mechanical ventilation or cardiopulmonary resuscitation
- •7) Does not want to participate or unable to provide consent
- •8) Determined to be unfit by the study investigator
研究者
相似试验
尚未招募
不适用
Prospective, Randomized, Open-label, Single center, Case Control Study To Evaluate Impact Of Eglandin® (Alprostadil) On Incidence Of Antibody-mediated Rejection According To Length Of Use In ABO-incompatible Living Donor Liver Transplant PatientKCT0006115Asan Medical Center160
已完成
不适用
Single Center,Study on Evaluation of use of,â??AYURCOVâ?? as add on therapy for Treatment of SARS-CoV-2 Infection in COVID-19 Patients,at Tertiary Care Center.CTRI/2020/06/026262Bhaktivedanta Hospital and Research Institute120
已完成
不适用
Single center, open-label, non-randomized, non-placebo-controlled study to investigate the metabolism, excretion pattern, mass balance, safety, tolerability and pharmacokinetics after single administration of 200 mg [14C]rogaratinib (oral solution) in healthy male subjectsNL-OMON46572Bayer AG6
已完成
不适用
Single center, open-label, non-randomized, non-placebo-controlled study to investigate the pharmacokinetics, metabolic disposition and mass balance after single administration of 5 mg [14C]BAY 1021189 (oral solution) in healthy male subjectsheart failureCardiovascular diseases10019280NL-OMON40889Bayer6
已完成
不适用
Single center, open-label, non-randomized, non-placebo-controlled study to investigate the pharmacokinetics, metabolic disposition and mass balance after single administration of 25 mg [14C]BAY 2433334 (oral solution) in healthy male participants.strokeNL-OMON50127Bayer AG6